Radiomics to predict tumor response to combination chemoradiotherapy in squamous cell carcinoma of the anal canal: a preliminary investigation

被引:0
|
作者
Vanzulli, Andrea [1 ,2 ,3 ]
Sciacqua, Lucilla Violetta [1 ]
Patti, Filippo [4 ]
Drebot, Roza [5 ]
Montin, Eros [6 ,7 ]
Lattanzi, Riccardo [6 ,7 ]
Lozza, Laura Anna Maria [4 ]
Villa, Sergio [4 ]
Scaramuzza, Davide [2 ]
机构
[1] Univ Milan, Diag & Intervent Radiol Residency Program, Milan, Italy
[2] Fdn IRCCS Ist Nazl Tumori, Dept Diag & Intervent Radiol, Milan, Italy
[3] Humanitas Univ, Dept Biomed Sci, Milan, Italy
[4] Fdn IRCCS Ist Nazl Tumori, Dept Radiat Oncol, Milan, Italy
[5] Univ Milan, Dept Oncol & Haemato Oncol, Milan, Italy
[6] New York Univ, Bernard & Irene Schwartz Ctr Biomed Imaging, Grossman Sch Med, Dept Radiol, New York, NY USA
[7] New York Univ, Ctr Adv Imaging Innovat & Res CAI2R, Dept Radiol, Grossman Sch Med, New York, NY USA
关键词
Anal canal; Carcinoma (squamous cell); Magnetic resonance imaging; Precision medicine; Radiomics; CANCER; HETEROGENEITY; CHEMOTHERAPY; RADIOTHERAPY; BREAST;
D O I
10.1186/s41747-025-00559-0
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
BackgroundUpfront combination chemoradiotherapy (CRT) represents the standard of care for patients affected by stage III squamous cell carcinoma (SCC) of the anal canal, achieving satisfactory results both in terms of overall survival and local disease control. However, a non-negligible fraction of patients obtain incomplete responses, highlighting the need for innovative prognostic tools. We report the preliminary results of a customized radiomic algorithm designed to predict tumor response to CRT in patients affected by SCC of the anal canal.MethodsWe manually annotated pretreatment T2-weighted turbo spin-echo images of 26 consecutive patients with stage III SCC of the anal canal treated with CRT at our institution from 2012 to 2022. Each patient was classified as complete response (CR, 17 patients), or non-complete response (non-CR, 9 patients) based on the absence or presence of residual disease at imaging and endoscopy after treatment. A total of 132 three-dimensional radiomic features were extracted for each patient and fed to a dedicated machine-learning classifier.ResultsModels trained with gray-level co-occurrence matrix features achieved the best performances (accuracy 0.846 +/- 0.064, sensitivity 0.900 +/- 0.122, specificity 0.833 +/- 0.175, area under receiver operating characteristics curve 0.867 +/- 0.055), highlighting a more homogeneous distribution of voxel intensities and lower spatial complexity in non-CR patients.ConclusionOur radiomic tool accurately predicted tumor response to CRT in patients with stage III SCC of the anal canal, highlighting a more homogeneous tissue composition in poor responders.Relevance statementThe more homogeneous radiomic texture observed in non-CR patients may be imputable to a dominant neoplastic clone with a relatively low mitotic index (therefore, limited tissue necrosis), intrinsically more resistant to CRT than faster-proliferating tumors.Key PointA non-negligible fraction of patients with anal SCC respond unsatisfactorily to CRT.Our radiomic model predicted response to CRT based on pretreatment MRI.We observed a more homogeneous tissue composition in poor responders.The slow proliferation of a dominant clone may explain non-CR to CRT.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Cetuximab in combination with cisplatin and 5-Fluorouracil induces dramatic response in metastatic refractory squamous cell carcinoma of the anal canal
    Rogers, Jane E.
    Silva, Ninoska N.
    Eng, Cathy
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2015, 6 (05) : E82 - E85
  • [42] Concurrent HPV Negative Squamous Cell Carcinoma of Anal Canal and Squamous Cell Carcinoma of Head and Neck
    Mehta, Vivek
    Khan, Uzma
    Pozzessere, Nicholas
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 : S181 - S182
  • [43] SQUAMOUS-CELL CARCINOMA ANTIGEN AS A MARKER FOR SQUAMOUS-CELL CARCINOMA OF THE ANAL-CANAL
    PETRELLI, NJ
    SHAW, N
    BHARGAVA, A
    DAUFELDT, J
    HERRERA, L
    STULC, JP
    SISCHY, B
    MITTELMAN, A
    JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (05) : 782 - 785
  • [44] Investigation of the EGFR and K-RAS gene status in squamous cell carcinoma of the anal canal
    Van Damme, N.
    Van Roy, N.
    Dernetter, P.
    Speleman, F.
    Bols, A.
    Van Dorpe, J.
    Nagy, N.
    Van Laethem, J.
    Pauwels, P.
    Peelers, M.
    ANNALS OF ONCOLOGY, 2008, 19 : 56 - 56
  • [45] Differentiated squamous intraepithelial neoplasia associated with squamous cell carcinoma of the anal canal
    Wasserman, Jason K.
    Bateman, Justin
    Mai, Kien T.
    HISTOPATHOLOGY, 2016, 68 (06) : 834 - 842
  • [46] Identification of key genes to predict response to chemoradiotherapy and prognosis in esophageal squamous cell carcinoma
    Cui, Yingying
    Wen, Jing
    Fu, Jianhua
    Leng, Changsen
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2024, 11
  • [47] EVALUATION OF SQUAMOUS-CELL CARCINOMA ANTIGEN AS A MARKER OF SQUAMOUS CARCINOMA OF THE ANAL-CANAL
    FONTANA, X
    LAGRANGE, JL
    FRANCOIS, E
    BOURRY, J
    CHAUVEL, P
    SORDAGE, M
    LAPALUS, F
    NAMER, M
    ANNALES DE GASTROENTEROLOGIE ET D HEPATOLOGIE, 1991, 27 (06): : 293 - 296
  • [48] The expression profile of biomarkers in squamous cell carcinoma of the anal canal and their influence on treatment outcomes: Preliminary results
    Moniz, Camila Motta Venchiarutti
    Riechelmann, Rachel Pimenta
    Ribeiro, Suilane Coelho
    Bariani, Giovanni Mendonca
    Rivelli, Thomas Giollo
    Ortega, Cintia
    Pereira, Allan Andresson Lima
    Meireles, Sibele Inacio
    Chen, Andre
    Nahas, Caio
    Sabagga, Jorge
    Coudry, Renata A.
    Hoff, Paulo Marcelo
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [49] The influence of HIV status on the duration of chemoradiotherapy for anal squamous cell carcinoma
    Zubi, A. R.
    Surridge, D. J.
    SOUTH AFRICAN JOURNAL OF SURGERY, 2022, 60 (01) : 16 - 21
  • [50] Inflammatory pathways confer resistance to chemoradiotherapy in anal squamous cell carcinoma
    Martin, D.
    Roedel, F.
    Hehlgans, S.
    Looso, M.
    Ziegler, P. K.
    Fleischmann, M.
    Diefenhardt, M.
    Fries, L.
    Kalinauskaite, G.
    Tinhofer, I.
    Zips, D.
    Gani, C.
    Roedel, C.
    Fokas, E.
    NPJ PRECISION ONCOLOGY, 2024, 8 (01)